The company has not filed an annual or quarterly report since its FY2018 10-K, filed Apr 1, 2019. Its latest SEC filing is a EFFECT from Aug 20, 2019.
10-K for FY2018, filed Apr 1, 2019
The sections below describe the company as of the FY2018 annual report.
Sold ZEMDRI, an intravenous antibiotic for complicated urinary tract infections, to specialty distributors and physician-owned infusion centers, and developed an oral antibiotic candidate.
10-K for FY2018, filed Apr 1, 2019We are a biopharmaceutical company passionately committed to developing and commercializing innovative antibacterial agents for multi-drug…View ↗
We are also currently developing C-Scape, which is in early-stage clinical development, as a product candidate, an orally administered…View ↗
The Company’s product revenue consists of the sales of ZEMDRI, which the Company began shipping to customers in July 2018. Prior to July…View ↗
Specialty distributors and infusion centers paid for ZEMDRI upon delivery; government agencies and a foundation funded research and development as the work was performed.
10-K for FY2018, filed Apr 1, 2019The Company’s product revenue consists of the sales of ZEMDRI, which the Company began shipping to customers in July 2018. Prior to July…View ↗
Revenue is recognized on product sales when the customer obtains control of the Company’s product, which occurs at a point in time (upon…View ↗
For revenue recognized as contract revenue, the Company evaluated Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts…View ↗
Funds received from third parties under contract or grant arrangements are recorded as revenue if the Company is deemed to be the principal…View ↗
In May 2017, the Company entered into an agreement with the Gates Foundation to discover drug candidates against gram-negative bacterial…View ↗
$8.7M
10-K for FY2018, filed Apr 1, 2019
$8.7M ↗
Specialty distributors and physician-owned infusion centers bought ZEMDRI and resold it to hospitals, medical centers or patients. U.S. government agencies and a nonprofit foundation funded development work through contracts and a grant.
10-K for FY2018, filed Apr 1, 2019The Company’s product revenue consists of the sales of ZEMDRI, which the Company began shipping to customers in July 2018. Prior to July…View ↗
For revenue recognized as contract revenue, the Company evaluated Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts…View ↗
Certain of the Company’s drug discovery and development activities are performed under contracts with the Gates Foundation and U.S.…View ↗
In May 2017, the Company entered into an agreement with the Gates Foundation to discover drug candidates against gram-negative bacterial…View ↗
No. It lost $186.5M in FY2018.
10-K for FY2018, filed Apr 1, 2019
10-K for FY2018, filed Apr 1, 2019
−$189.2MView ↗
10-K for FY2018, filed Apr 1, 2019
−$186.5MView ↗
10-K for FY2018, filed Apr 1, 2019
−$174MView ↗
8-K, filed Jul 29, 2019
As previously disclosed, on June 20, 2019, the Company entered into an asset purchase agreement (the ‘Plazomicin Agreement’) with Cipla USA…View ↗
8-K, filed Jun 26, 2019
On June 20, 2019, the Company entered into another asset purchase agreement (the ‘C-Scape Agreement’) with Cipla, pursuant to which Cipla…View ↗
8-K, filed May 6, 2019
As previously disclosed, on April 15, 2019, Achaogen, Inc. (the ‘Company’) filed a voluntary petition for bankruptcy protection under…View ↗
Shrank. Revenue fell 56% in 4 years, from $20M in FY2014 to $8.7M in FY2018, about 19% a year.
Plazomicin reached commercial sales
Plazomicin moved from a clinical-stage candidate to an approved, commercially available antibiotic for complicated urinary tract infections.
10-K for FY2015, filed Mar 15, 2016 10-K for FY2018, filed Apr 1, 2019We are a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel…View ↗
We are a biopharmaceutical company passionately committed to developing and commercializing innovative antibacterial agents for multi-drug…View ↗
Competes with Allergan, Pfizer, Melinta Therapeutics, Merck, Tetraphase Pharmaceuticals, Merck &, Nabriva Therapeutics, Shionogi, Iterum, and Spero Therapeutics
10-K for FY2018, filed Apr 1, 2019The competition in the antibiotics market is intense. Our clinical development program supports ZEMDRI’s differentiated profile from both…View ↗
Loading...
